Dysbiotic microbiota interactions in Crohn’s disease

Autor: Esther Caparrós, Reiner Wiest, Michael Scharl, Gerhard Rogler, Ana Gutiérrez Casbas, Bahtiyar Yilmaz, Marcin Wawrzyniak, Rubén Francés

Publikováno v: Gut Microbes, Vol 13, Iss 1 (2021)

Crohn’s disease (CD) is a major form of inflammatory bowel disease characterized by transmural inflammation along the alimentary tract. Changes in the microbial composition and reduction in species diversity are recognized as pivotal hallmarks in d

Externí odkaz: https://doaj.org/article/de1a757ebdb34bd49a45437b4961c880

Real‐world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA‐SWITCH study

Autor: María José Casanova, Óscar Nantes, Pilar Varela, Milagros Vela‐González, Montserrat Rivero, Olivia Sierra‐Gabarda, Sabino Riestra, Manuel Barreiro‐de Acosta, María del Mar Martín‐Rodríguez, Carla Jerusalén Gargallo‐Puyuelo, Cristina Reygosa, Roser Muñoz, Irene García de la Filia‐Molina, Andrea Núñez‐Ortiz, Lilyan Kolle, Margalida Calafat, José María Huguet, Eva Iglesias‐Flores, Teresa de Jesús Martínez‐Pérez, Orencio Bosch, José María Duque‐Alcorta, Santiago Frago‐Larramona, Manuel Van Domselaar, Víctor Manuel González‐Cosano, Luis Bujanda, Saioa Rubio, Alejo Mancebo, Beatriz Castro, Santiago García‐López, Ruth de Francisco, Laura Nieto‐García, Viviana Laredo, Ana Gutiérrez‐Casbas, Francisco Mesonero, Eduardo Leo‐Carnerero, Fiorella Cañete, Lucía Ruiz, Beatriz Gros, María del Moral‐Martínez, Cristina Rodríguez, María Chaparro, Javier P. Gisbert

Publikováno v: Alimentary Pharmacology & Therapeutics.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9d12c3a62012b4169d80e6214d4b8609
https://doi.org/10.1111/apt.17525

Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST):an open-label, multicentre, randomised phase 3b trial

Autor: Silvio Danese, Severine Vermeire, Geert D'Haens, Julian Panés, Axel Dignass, Fernando Magro, Maciej Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Ivana Bravata, Frederic Lavie, Marco Daperno, Milan Lukáš, Alessandro Armuzzi, Mark Löwenberg, Daniel R Gaya, Laurent Peyrin-Biroulet, Rodolfo Rocca, Susana Lopes, Flavio Caprioli, Sandro Ardizzone, Ana Echarri Piudo, Paolo Gionchetti, Xavier Roblin, Ursula Seidler, David Andersson, Kamal Patel, Pierre Desreumaux, Simone Saibeni, Gustav From, Miroslav Fedurco, Milos Gregus, Yoram Bouhnik, Andreas Luegering, Rocco Cosintino, Ivan Bunganic, Jaime Ramos, Mariam Aguas Peris, Olivier Dewit, Mariabeatrice Principi, Emma Wesley, Paula Lago, Stephane Nancey, María Dolores Martín Arranz, Pieter Hindryckx, Ambrogio Orlando, Andrea Geccherle, Maria Laura Annunziata, Bu'hussain Hayee, Jozef Balaz, Francisco Portela, Cyrielle Gilletta, Torsten Kucharzik, Miguel Mínguez, Javier Pérez Gisbert, Ana Gutiérrez Casbas, Edouard Louis, Marco Marino, Gareth Parkes, Fraser Cummings, Bindia Jharap, Jens Kjeldsen, Luís Correia, Paula Ministro, Matthias Ebert, Erik Hertervig, Dirk Staessen, Joris Dutré, Arnaud Colard, Graham Morrison, Henning Glerup, Jens Frederik Dahlerup, Frank Wolfhagen, Marian Batovsky, Martin Molnar, Barbora Kadleckova, Paulo Caldeira, David Laharie, Xavier Hebuterne, Bruno Bonaz, Matthieu Allez, Andreas Fischer, Joaquín Ernesto Hinojosa Del Val, Miriam Mañosa Ciria, Jose Manuel Herrera Justiniano, Charlotte Soderman, Rajiv Chandy, Craig Mowat, Peter Irving, Jan Fallingborg, Jan Matous, Tomas Douda, Romain Altwegg, Jose Manuel Benitez, María Teresa Arroyo Villarino, Jordi Guardiola Capón, Daniel Ginard Vicenc, Pieter Dewint, Sven Almer, Sebastien Kindt

Publikováno v: Danese, S, Vermeire, S, D'Haens, G, Panés, J, Dignass, A, Magro, F, Nazar, M, Le Bars, M, Lahaye, M, Ni, L, Bravata, I, Lavie, F, Daperno, M, Lukáš, M, Armuzzi, A, Löwenberg, M, Gaya, D R, Peyrin-Biroulet, L & STARDUST study group 2022, ' Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST) : an open-label, multicentre, randomised phase 3b trial ', The Lancet Gastroenterology and Hepatology, vol. 7, no. 4, pp. 294-306 . https://doi.org/10.1016/S2468-1253(21)00474-X
lancet. Gastroenterology & hepatology, 7(4), 294-306. Elsevier Limited
The Lancet Gastroenterology and Hepatology, 7(4), 294-306. Elsevier Ltd

Background: A treat-to-target strategy, in which strictly defined treatment targets facilitate decision making in clinical practice, is advocated as an optimised management approach for some chronic disorders. The aim of the STARDUST trial was to ass

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c41ea76bc7f88c535499cddcf9ba8ad
https://pure.au.dk/portal/da/publications/treat-to-target-versus-standard-of-care-for-patients-with-crohns-disease-treated-with-ustekinumab-stardust(6e02a521-a146-4afb-857c-d91bbe745a10).html

Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn's Disease Patients on Ustekinumab

Autor: María Chaparro, Iria Baston-Rey, Estela Fernández Salgado, Javier González García, Laura Ramos, María Teresa Diz-Lois Palomares, Federico Argüelles-Arias, Eva Iglesias Flores, Mercedes Cabello, Saioa Rubio Iturria, Andrea Núñez Ortiz, Mara Charro, Daniel Ginard, Carmen Dueñas Sadornil, Olga Merino Ochoa, David Busquets, Eduardo Iyo, Ana Gutiérrez Casbas, Patricia Ramírez de la Piscina, Marta Maia Boscá-Watts, Maite Arroyo, María José García, Esther Hinojosa, Jordi Gordillo, Pilar Martínez Montiel, Benito Velayos Jiménez, Cristina Quílez Ivorra, Juan María Vázquez Morón, José María Huguet, Yago González-Lama, Ana Isabel Muñagorri Santos, Víctor Manuel Amo, María Dolores Martín Arranz, Fernando Bermejo, Jesús Martínez Cadilla, Cristina Rubín de Célix, Paola Fradejas Salazar, Antonio López San Román, Nuria Jiménez, Santiago García-López, Anna Figuerola, Itxaso Jiménez, Francisco José Martínez Cerezo, Carlos Taxonera, Pilar Varela, Ruth de Francisco, David Monfort, Gema Molina Arriero, Alejandro Hernández-Camba, Francisco Javier García Alonso, Manuel Van Domselaar, Ramón Pajares-Villarroya, Alejandro Núñez, Francisco Rodríguez Moranta, Ignacio Marín-Jiménez, Virginia Robles Alonso, María del Mar Martín Rodríguez, Patricia Camo-Monterde, Iván García Tercero, Mercedes Navarro-Llavat, Lara Arias García, Daniel Hervías Cruz, Sebastian Kloss, Alun Passey, Cynthia Novella, Eugenia Vispo, Manuel Barreiro-de Acosta, Javier P. Gisbert

Publikováno v: Journal of Clinical Medicine
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Journal of Clinical Medicine; Volume 11; Issue 15; Pages: 4518
r-FISABIO. Repositorio Institucional de Producción Científica
Scientia
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Dipòsit Digital de la UB
Universidad de Barcelona
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante

Malaltia de Crohn; Factors predictius; Ustekinumab Enfermedad de Crohn; Factores predictivos; Ustekinumab Crohn’s disease; Predictive factors; Ustekinumab Ustekinumab has shown efficacy in Crohn’s Disease (CD) patients. To identify patient profil

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6cdcac871079c044b252b8559b16c0b
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=16859

Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry

Autor: Diego Casas-Deza, Luis Javier Lamuela-Calvo, Fernando Gomollón, José Miguel Arbonés-Mainar, Berta Caballol, Javier P Gisbert, Montserrat Rivero, Eugenia Sánchez-Rodríguez, Lara Arias García, Ana Gutiérrez Casbas, Olga Merino, Lucía Márquez, Viviana Laredo, María Dolores Martín-Arranz, Pilar López Serrano, Sabino Riestra Menéndez, Carlos González-Muñoza, Luisa de Castro Parga, Marta Calvo Moya, Esteban Fuentes-Valenzuela, Maria Esteve, Marisa Iborra, Miguel Dura Gil, Manuel Barreiro-De Acosta, Rufo Humberto Lorente-Poyatos, Noemí Manceñido, Margalida Calafat, Iago Rodríguez-Lago, Jordi Guardiola Capo, Maria Antonia Payeras, Víctor Jair Morales Alvarado, Carlos Tardillo, Luis Bujanda, José Fernando Muñoz-Nuñez, Yolanda Ber Nieto, Fernando Bermejo, Pedro Almela, Mercè Navarro-Llavat, Pilar Martínez Montiel, Cristina Rodríguez Gutiérrez, Manuel Van Domselaar, Eva Sesé, Teresa Martínez Pérez, Elena Ricart, María Chaparro, María José García, Antonio López-Sanromán, Beatriz Sicilia, Beatriz Orts, Alicia López-García, Eduardo Martín-Arranz, José Lázaro Pérez-Calle, Ruth de Francisco, Esther García-Planella, Eugeni Domènech, y Santiago García-López

Publikováno v: JOURNAL OF CROHNS & COLITIS
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
Journal of Crohn's & colitis
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
Journal of Crohns & Colitis
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau

Background and Aims Clinical trials and real-life studies with ustekinumab in Crohn’s disease [CD] have revealed a good efficacy and safety profile. However, these data are scarcely available in elderly patients. Therefore, we aim to assess the eff

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c68c5baab4813c0e1f8f7d3d03eedc6
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=7186